{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Grade+2+Glioma", "query": { "condition": "Grade 2 Glioma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 168, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Grade+2+Glioma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T22:42:37.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03257631", "title": "A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasms", "Medulloblastoma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 53, "start_date": "2017-09-18", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 6, "location_summary": "Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257631" }, { "nct_id": "NCT02414165", "title": "The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Toca 511", "type": "BIOLOGICAL" }, { "name": "Toca FC", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 403, "start_date": "2015-11-30", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414165" }, { "nct_id": "NCT07110246", "title": "Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF V600 Mutation", "Low-grade Glioma", "Low Grade Glioma of Brain", "Recurrent Low Grade Glioma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Specimen Collection", "type": "PROCEDURE" }, { "name": "Optional Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "12 Months to 25 Years" }, "enrollment_count": 96, "start_date": "2025-11-07", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07110246" }, { "nct_id": "NCT01116661", "title": "Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "5-Aminolevuline Acid (ALA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 199, "start_date": "2010-08", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01116661" }, { "nct_id": "NCT05099003", "title": "A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 132, "start_date": "2022-05-31", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 109, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05099003" }, { "nct_id": "NCT03632317", "title": "A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 0, "start_date": "2019-10", "completion_date": "2025-10", "has_results": false, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03632317" }, { "nct_id": "NCT00788125", "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 7, "start_date": "2008-09-03", "completion_date": "2022-07-30", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788125" }, { "nct_id": "NCT00030108", "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Leukemia", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 30, "start_date": "2001-11", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030108" }, { "nct_id": "NCT03914742", "title": "BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IDH1 Mutation", "IDH2 Mutation", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma" ], "interventions": [ { "name": "PARP Inhibitor BGB-290", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2020-02-16", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914742" }, { "nct_id": "NCT04923126", "title": "SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Low-Grade Glioma", "Recurrent Low-Grade Glioma", "Progressive Low-Grade Glioma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "2 Years to 24 Years" }, "enrollment_count": 132, "start_date": "2021-06-21", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-06-25T22:42:37.754Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923126" } ] }